Biosimilar Clinical Approach

By HEOR Staff Writer

June 23, 2025

What is the biosimilar clinical approach, and how is it changing biosimilar approvals in the EU? The biosimilar clinical approach—as outlined in the latest
FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...
Canada Launches Consultation for Essential Prescription Drugs List
ACIP Vaccine Policy Concerns
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Efficacy of Ultomiris Pediatric TMA Treatment
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
EMA 2024 Report Highlights: Innovations in Medicine Approval and Regulatory A...
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies